Annuaire du CSM
Dr Christopher MONTEMAGNO
Chargé de Recherche - Equipe Cellules Souches et Tumeurs du CerveauTel. +377 97 77 44 10
Email : [javascript protected email address]
Thèmes de recherche développés
Radiothérapie et tumeurs cérébrales
Publications CSM
-
Exploiting Integrin-αVβ3 to Enhance Radiotherapy Efficacy in Medulloblastoma via Ferroptosis
Gotorbe C, Segui F, Echavidre W, Durivault J, Blanchard T, Vial V, Pagnuzzi-Boncompagni M, Villeneuve R, Amblard R, Garnier N, Ortholan C, Serrano B, Picco V, Pouyssegur J, Vucetic M, Montemagno C
Curr. Oncol. 31, 7390–7402 -
Integrin Targeting and Beyond: Enhancing Cancer Treatment with Dual-Targeting RGD (Arginine–Glycine–Aspartate) Strategies
Bogdanovic B, Fagret D, Ghezzi C, Montemagno C
Pharmaceuticals 17(11), 1556 -
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001
Montemagno C, Jacquel A, Pandiani C, Rastoin O, Dawaliby R, Schmitt T, Bourgoin M, Palenzuela H, Rossi A-L, Ambrosetti D, Durivault J, Luciano F, Borchiellini D, Le Du J, Pires Gonçalves L C, Auberger P, Benhida R, Kinget L, Beuselinck B, Ronco C, Pagès G, Dufies M
J Exp Clinical Cancer Research 43(1):86 -
A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma
Montemagno C, Durivault J, Gastaldi C, Dufies M, Vial V, He X, Ambrosetti D, Kamenskaya A, Négrier S, Bernhard J-C, Borchiellini D, Cao Y, Pagès G
mol 21 Feb 2023, 45 -
Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
Echavidre W, Durivault J, Gotorbe C, Blanchard T, Pagnuzzi M, Vial V, Raes F, Broisat A, Villeneuve R, Amblard R, Garnier N, Ortholan C, Faraggi M, Serrano B, Picco V, Montemagno C
Cancer Res Commun 3(12):2483-2496 -
Quantitative analysis of 99mTc‐pertechnetate thyroid uptake with a large‐field CZT gamma camera: feasibility and comparison between SPECT/CT and planar acquisitions
Serrano B, Amblard R, Beaumont T, Hugonnet F, Dietz M, Berthier F, Garnier N, Villeneuve R, Nataf V, Mocquot F, Montemagno C, Faraggi M, Paulmier B
EJNMMI Phys 10, 45 (2023) -
Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future
Echavidre W, Fagret D, Faraggi M, Picco V, Montemagno C
Cancers 15(19), 4839 -
Should evidence of an autolysosomal de-acidification defect in Alzheimer and Parkinson diseases call for caution in prescribing chronic PPI and DMARD?
Giuliano S, Montemagno C, Domdom M-A, Teisseire M, Brest P, Klionsky D J, Hofman P, Pagès G, Mograbi B
Autophagy 19(10):2800-2806 -
Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma
Pagnuzzi M, Picco V, Vial V, Planas-Bielsa V, Vandenberghe A, Daubon T, Derieppe M-A, Montemagno C, Durivault J, Grépin R, Martial S, Doyen J, Gavard J, Pagès G
Cancers 14(1) : 70 -
Cancer-associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti- angiogenic therapy
Ambrosetti D, Coutts M, Paoli C, Durand M, Borchiellini D, Montemagno C, Rastoin O, Borderie A, Grépin R, Rioux-Leclercq N, Bernhard J-C, Pagès G, Dufies M
BJU Int 2022 Jan;129(1):80-92 -
Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future?
Echavidre W, Picco V, Faraggi M, Montemagno C
Pharm. 14(5) : 1053 -
Opposing Roles of Vascular Endothelial Growth Factor C in Metastatic Dissemination and Resistance to Radio/Chemotherapy: Discussion of Mechanisms and Therapeutic Strategies
Montemagno C, Luciano F, Pagès G
Methods Mol Biol 2475:1-23 -
Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma
Hagege A, Saada-Bouzid E, Ambrosetti D, Rastoin O, Boyer J, He X, Rousset J, Montemagno C, Doyen J, Pedeutour F, Parola J, Bourget I, Luciano F, Bozec A, Cao Y, Pagès G, Dufies M
Cell Reports Medicine 3(9): 100659 -
Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas
Dumond A, Montemagno C, Vial V, Grépin R, Pagès G
Cells 10(5): 1222 -
Cancer associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to antiangiogenic therapy
Ambrosetti D, Coutts M, Paoli C, Durand M, Borchiellini D, Montemagno C, Rastoin O, Borderie A, Grépin R, Rioux-Leclercq N, Bernhard J-C, Pagès G, Dufies M
BJU Int doi: 10.1111/bju.15506. -
In vivo monitoring of the therapeutic efficacy of a CXCR1/2 inhibitor with 18F-FDG PET/CT imaging in experimental head and neck carcinoma: A feasibility study
Montemagno C, Serrano B, Durivault J, Nataf V, Mocquot F, Amblard R, Vial V, Ronco C, Benhida R, Dufies M, Faraggi M, Pagès G
Biochem Biophys Rep 27: 101098 -
Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma
Dumond A, Brachet E, Durivault J, Vial V, Puszko A K, Lepelletier Y, Montemagno C, Pagnuzzi M, Hermine O, Garbay C, Lagarde N, Montes M, Demange L, Grépin R, Pagès G
J Exp Clinical Cancer Research 40: 33 -
Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
Montemagno C, Cassim S, De Leiris N, Durivault J, Faraggi M, Pagès G
Int J Mol Sci 22, 6413 -
From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma
Montemagno C, Cassim S, Pouyssegur J, Broisat A, Pagès G
Int J Mol Sci 21(11): 4067 -
Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine
Montemagno C, Pagès G
Cancers 12(4): 821 -
Resistance to anti-angiogenic therapies: A mechanism depending on the time of exposure to the drugs
Montemagno C, Pagès G
Front Cell Dev Biol 8: 584 -
Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma.
Montemagno C, Hagege A, Borchiellini D, Thamphya B, Rastoin O, Ambrosetti D, Iovanna J, Rioux-Leclercq N, Porta C, Négrier S, Ferrero J-M, Chamorey E, Pagès G, Dufies M
Oncoimmunology 9:1, 1846901 -
Targeting mesothelin in pancreatic ductal adeno-carcinoma (PDAC)
Montemagno C, Pagès G
J Cell Immunol 2(2): 65-67 -
99mTc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma
Montemagno C, Cassim S, Trichanh D, Savary C, Pouyssegur J, Pagès G, Fagret D, Broisat A, Ghezzi C
Cancers 11(10): 1531